The O.H.I.O. Fund Invests in T45 Labs' Second Fund to Advance Cardiovascular Medtech
T45 Labs has secured an undisclosed investment in its T45 Fund-II from private funds advised by The O.H.I.O. Fund. This capital injection is intended to support the development of a portfolio of minimally invasive cardiovascular device companies, leveraging medical innovations originating from institutions like the Cleveland Clinic. T45 Labs operates as a medtech incubator that de-risks breakthrough technologies through clinical and regulatory milestones to prepare them for acquisition. Key portfolio companies include Advanced NanoTherapies (ANT), which recently closed $31 million in Series B funding, as well as Mitria Medical, VahatiCor, and NuevoSono.
Topics: cardiovascular technology economic development medtech venture capital